Johnson & Johnson has been dealing for years with thousands of lawsuits related to its talc-based products, which plaintiffs claim gave them cancer. This issue has somewhat affected the drugmaker's ...

Investors are paying a premium for Johnson & Johnson (JNJ) stock. It trades at 29.2 times earnings, compared to 22.9 for the ...

MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to ...

Monday - Friday, 6:00 - 7:00 PM ET CNBC's Jim Cramer on Thursday told investors why he thinks the stock of Johnson & Johnson is performing well this year even as the broader healthcare sector lags.

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, ...

Johnson & Johnson has unveiled a plan to separate from its $9 billion orthopedics business, transforming it into a standalone company. (Angus Liu/Fierce Pharma) Two years after spinning off its $15 ...

Monday - Friday, 6:00 - 7:00 PM ET As Wall Street navigates a jam-packed start to earnings season, CNBC's Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its ...

Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 ...

Johnson & Johnson will spend $2 billion over the next 10 years renting a 160,000-square-foot facility at Fujifilm Diosynth's massive manufacturing complex in Holly Springs, N.C. ((Photo by Cristina ...

Add Yahoo as a preferred source to see more of our stories on Google. On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked ...

Johnson & Johnson claims a former associate director now employed by Summit Therapeutics downloaded more than 7,000 confidential internal documents to her personal device before and after her ...